Pharmaceutical spending in many other countries has had a steep increase in the last decade. The Portuguese Government has adopted several measures to reduce pharmaceutical expenditure growth, ranging from increased co-payments to price decreases determined administratively. Promotion of generic...

In early 2004, the U.S. Government initiated the Medicare Discount Drug Card Program, under which a large amount of pharmacy-level price data pertaining to over 800 drugs has been released weekly on the Medicare Web site continuously between May 29, 2004 and October 2005. This extensive...

In early 2004, the U.S. Government initiated the Medicare Discount Drug Card Program, which created a market for drug cards that allowed their subscribers to obtain discounts on their prescription drug purchases. Pharmacy-level prices for several drugs were posted on the program website weekly...

The United States has recently — and belatedly — come to recognize opioid addiction as a public health crisis. What has gone mostly unrecognized is the degree to which this crisis is intertwined with U.S. intellectual property law and related elements of U.S. innovation policy. Innovation...

We investigate the effect of variations in the price of opium in Afghanistan on per capita dispensation of prescription opioids in the US. Quarterly county-level data for 2003-2016 indicate that reductions in opium prices significantly increase the quantity of opioids prescribed. The increase...

Recent political events have thrust the bulk negotiation of drug prices by Medicare and Medicaid back into the spotlight. Yet, even if politically feasible, there is no clear framework for negotiating prices of new drugs with uncertain target populations — for example, due to imprecise...

In this paper, I study the effect of parallel trade (cross border resale of goods without the authorization of the manufacturer) on pharmaceutical regulation in a North-South framework with a firms endogenous decision to export to the South. Governments in both countries may limit prices...

This paper analyzes the optimal content regulation of direct-to-consumer advertisement (DTCA) in a pharmaceutical market, with particular focus on the distinction between product and enlightenment advertisement. Firms are allowed to freely promote their own specific products under product DTCA,...